Gilead Sciences Inc. is one of the world biggest biopharmaceutical research and development companies. It develops and promotes products on the drugs market for the treatment of patients with life-threatening illnesses such as HIV/AIDS, liver disease and severe cardiovascular and respiratory diseases. Geographical revenue diversification (share): USA: 61.5%, Europe: 17.8%, Japan: 6.0%, Other countries: 14.7%. The company was founded in California in 1987.
A growth in share prices will be facilitated by the introduction of a new line of products into the market, increased research in the fields of Oncology and Hematology as well of the appointment of world-renowned expert Alessandro Riva (who previously headed the global Oncology division at Novartis) to the post of Senior Vice President. Moreover, Gilead Sciences has a high level of profitability. Throughout the first three quarters of 2016, the ratio of net profit to revenue was no lower than 45%. Return on equity did not fall below 87.95% and return on assets did not fall below 28.11%. A low debt load (the ratio of net debt to EBITDA amounts to a negative value of -0.22, thanks to high stock liquidity) has a positive effect on the level of financial stability.
Investment period ends: 16/06/2017
Expected yield is calculated according to 96% capital protection and the price of the base asset at expiry, equal to 98 USD.
Gilead Sciences share price is readying to leave the Ichimoku indicator cloud upwards and an upwards trend is starting to form. The significant technical levels are: 47.55; 53.42; 57.17; 58.82; 63.75; 68.23; 71.53; 77.15; 82.00; 85.16; 88.38; 94.00; 97.67; 102.85; 106.24; 109.87; 115.95; 120.36.